Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORGESIC vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Relief of discomfort associated with acute painful musculoskeletal conditions
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Orphenadrine is extensively metabolized in the liver via oxidative N-demethylation and hydroxylation; aspirin is hydrolyzed to salicylic acid, which is primarily metabolized in the liver by conjugation (glucuronidation and glycine conjugation) and oxidation; caffeine is metabolized in the liver via cytochrome P450 1A2 (CYP1A2) to paraxanthine, theobromine, and theophylline.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
~90% bound to albumin and alpha-1-acid glycoprotein
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
1.5–2.0 L/kg; indicates extensive tissue distribution
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: ~70% (first-pass metabolism reduces absolute bioavailability); Intramuscular: ~100%
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
GFR 30-59 m L/min: reduce dose by 50% (maximum 1 tablet twice daily). GFR <30 m L/min: avoid use due to risk of accumulation.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Child-Pugh Class B: reduce dose by 50% (maximum 1 tablet twice daily). Child-Pugh Class C: contraindicated.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Not recommended for patients under 18 years of age due to lack of safety and efficacy data.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Start with 1 tablet twice daily; titrate slowly due to increased risk of anticholinergic effects (confusion, urinary retention).
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
No FDA black box warning.
None.
May impair mental and/or physical abilities required for driving or operating machinery due to anticholinergic effects (e.g., drowsiness, blurred vision),Use with caution in patients with glaucoma, prostatic hypertrophy, or gastrointestinal obstruction due to anticholinergic effects,Aspirin component increases risk of bleeding, particularly in patients with bleeding disorders or on anticoagulant therapy,Reye's syndrome risk in children and teenagers with viral infections,Hypersensitivity reactions including anaphylaxis may occur,Renal impairment may increase risk of salicylate toxicity
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to any component,Peptic ulcer or gastrointestinal bleeding,Severe renal impairment (creatinine clearance <10 m L/min),Severe hepatic impairment,Bleeding disorders (e.g., hemophilia),Concurrent use of anticoagulants or antiplatelet drugs (relative),Children and teenagers with varicella or influenza-like symptoms (due to Reye's syndrome risk),Glaucoma (angle-closure), prostatic hypertrophy, or gastrointestinal obstruction (relative, due to anticholinergic effects)
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
Avoid alcohol. Take with food or milk to minimize GI irritation. No specific food interactions beyond alcohol and potential for increased gastric irritation with aspirin.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
Norgesic contains orphenadrine citrate, aspirin, and caffeine. Aspirin: First trimester: possible increased risk of miscarriage and cardiac defects; third trimester: premature closure of ductus arteriosus and oligohydramnios; avoid in third trimester. Orphenadrine: limited human data; animal studies not sufficient; avoid in pregnancy unless benefit outweighs risk. Caffeine: considered low risk at moderate doses.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Orphenadrine: excreted in breast milk; M/P ratio unknown; potential for anticholinergic effects in infant. Aspirin: excreted in breast milk; risk of Reye's syndrome if infant has viral illness; avoid breastfeeding while using aspirin. Caffeine: low levels in milk; generally considered safe in moderate amounts. Not recommended during breastfeeding.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
No standard dosing adjustments established. Avoid use in pregnancy, especially third trimester, due to aspirin component. If necessary, use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may affect caffeine elimination, but no specific dose adjustment recommended.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
Norgesic (orphenadrine/aspirin/caffeine) is used for musculoskeletal pain. Orphenadrine has anticholinergic properties; use cautiously in elderly, glaucoma, or prostatic hypertrophy. May cause drowsiness and impair motor skills. Avoid in myasthenia gravis. Monitor for GI bleeding due to aspirin.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Take with food or milk to reduce GI upset.,Avoid alcohol and other CNS depressants.,Do not drive or operate machinery until you know how this medication affects you.,Report signs of bleeding (bruising, black stools) or anticholinergic effects (dry mouth, blurred vision, constipation).,Do not exceed recommended dose; orphenadrine can cause serious anticholinergic toxicity.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORGESIC vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
NORGESIC is a Muscle Relaxant that works by NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORGESIC and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORGESIC is: 1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORGESIC and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORGESIC is classified as Category C. Norgesic contains orphenadrine citrate, aspirin, and caffeine. Aspirin: First trimester: possible increased risk of miscarriage and cardiac defects; third trimester: premature clos. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.